IL155225A0 - Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders - Google Patents

Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders

Info

Publication number
IL155225A0
IL155225A0 IL15522501A IL15522501A IL155225A0 IL 155225 A0 IL155225 A0 IL 155225A0 IL 15522501 A IL15522501 A IL 15522501A IL 15522501 A IL15522501 A IL 15522501A IL 155225 A0 IL155225 A0 IL 155225A0
Authority
IL
Israel
Prior art keywords
treatment
cognitive disorders
inverse agonists
combination use
acetylcholinesterase inhibitors
Prior art date
Application number
IL15522501A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Neurogen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Neurogen Corp filed Critical Pfizer Prod Inc
Publication of IL155225A0 publication Critical patent/IL155225A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
IL15522501A 2000-10-17 2001-10-15 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders IL155225A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24114500P 2000-10-17 2000-10-17
PCT/IB2001/001934 WO2002032412A2 (en) 2000-10-17 2001-10-15 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
IL155225A0 true IL155225A0 (en) 2003-11-23

Family

ID=22909428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15522501A IL155225A0 (en) 2000-10-17 2001-10-15 Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders

Country Status (14)

Country Link
US (2) US20020151591A1 (es)
EP (1) EP1328294A2 (es)
JP (1) JP2004511512A (es)
KR (1) KR20030046509A (es)
AR (1) AR030893A1 (es)
AU (2) AU9411701A (es)
CA (1) CA2426120A1 (es)
HU (1) HUP0302476A3 (es)
IL (1) IL155225A0 (es)
NZ (1) NZ525103A (es)
PE (1) PE20020473A1 (es)
UY (1) UY26970A1 (es)
WO (1) WO2002032412A2 (es)
ZA (1) ZA200302918B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10119862A1 (de) * 2001-04-24 2002-11-07 Hf Arzneimittelforsch Gmbh Verwendung von Galanthamin zur Behandlung von Krankheitserscheinungen des zentralen Nervensystems aufgrund von Intoxikationen mit psychotropen Substanzen
CA2511599A1 (en) * 2002-12-24 2004-07-15 Neurochem (International) Limited Therapeutic formulations for the treatment of beta-amyloid related diseases
US8299062B2 (en) * 2003-09-17 2012-10-30 Franklin Volvovitz Pharmaceutical compositions and methods for preventing, treating, or reversing neuronal dysfunction
US20070054940A1 (en) * 2003-09-19 2007-03-08 Eisai Co., Ltd. Remedy for down's syndrome
TW200533371A (en) * 2004-04-15 2005-10-16 Dainippon Pharmaceutical Co Medicament comprising a combination of an acetylcholinesterase inhibitor and a 5-substituted-3-oxadiazolyl-1,6-naphthyridin-2(1h)-one derivative
US20050267076A1 (en) * 2004-05-14 2005-12-01 Johns Hopkins University Method for improving cognitive function
PA8640801A1 (es) * 2004-08-09 2006-08-03 Warner Lambert Co Nuevos inhibidores de la recaptacion de norepinefrina de quinoxalinona para el tratamiento de trastornos del sistema nervioso central
CN100382802C (zh) * 2005-08-08 2008-04-23 赵德禄 治疗自主神经系统功能紊乱的药物
AU2007267988B2 (en) 2006-05-22 2013-02-21 The Board Of Trustees Of The Leland Stanford Junior University Pharmacological treatment of cognitive impairment
CA2666219C (en) 2006-10-16 2017-02-07 Bionomics Limited Novel anxiolytic compounds
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
WO2008065141A1 (en) 2006-11-30 2008-06-05 Probiodrug Ag Novel inhibitors of glutaminyl cyclase
ZA200905537B (en) 2007-03-01 2010-10-27 Probiodrug Ag New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2012002993A (es) 2009-09-11 2012-04-19 Probiodrug Ag Derivados heterociclicos como inhibidores de ciclasa glutaminilo.
CA2789014C (en) 2010-02-09 2019-01-15 Michela Gallagher Methods and compositions for improving cognitive function
JP6026284B2 (ja) 2010-03-03 2016-11-16 プロビオドルグ エージー グルタミニルシクラーゼの阻害剤
MX2012010470A (es) 2010-03-10 2012-10-09 Probiodrug Ag Inhibidores heterociclicos d ciclasa de glutaminilo (qc, ec .3 2. 5).
US8541596B2 (en) 2010-04-21 2013-09-24 Probiodrug Ag Inhibitors
WO2012068161A1 (en) 2010-11-15 2012-05-24 Agenebio, Inc. Pyridazine derivatives, compositions and methods for treating cognitive impairment
WO2012116415A1 (en) 2011-03-02 2012-09-07 Bionomics Limited Novel small-molecules as therapeutics
WO2012123563A1 (en) 2011-03-16 2012-09-20 Probiodrug Ag Benz imidazole derivatives as inhibitors of glutaminyl cyclase
CA2835450C (en) 2011-05-12 2020-05-12 Bionomics Limited Methods for preparing naphthyridines
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
CA2904767C (en) 2013-03-15 2022-06-21 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
EP3083569B1 (en) 2013-12-20 2022-01-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2016191288A1 (en) 2015-05-22 2016-12-01 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
CN108026107B (zh) 2015-06-19 2021-07-30 艾吉因生物股份有限公司 用于治疗认知损害的苯并二氮杂环庚三烯衍生物、组合物和方法
US20180170941A1 (en) 2016-12-19 2018-06-21 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
BR112019012821A2 (pt) 2016-12-19 2019-11-26 Agenebio Inc derivados de benzodiazepina, composições e métodos para o tratamento do comprometimento cognitivo
EP3461819B1 (en) 2017-09-29 2020-05-27 Probiodrug AG Inhibitors of glutaminyl cyclase
CA3104478A1 (en) 2018-06-19 2019-12-26 Agenebio, Inc. Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
WO2024039886A1 (en) 2022-08-19 2024-02-22 Agenebio, Inc. Benzazepine derivatives, compositions, and methods for treating cognitive impairment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4374138A (en) * 1981-11-13 1983-02-15 Warner-Lambert Company Antibacterial amide compounds, compositions, and methods of use
US5870723A (en) * 1994-11-28 1999-02-09 Pare, Jr.; David Ferrin Tokenless biometric transaction authorization method and system
US6088683A (en) * 1996-08-21 2000-07-11 Jalili; Reza Secure purchase transaction method using telephone number
US6016476A (en) * 1997-08-11 2000-01-18 International Business Machines Corporation Portable information and transaction processing system and method utilizing biometric authorization and digital certificate security
US6143760A (en) * 1997-08-25 2000-11-07 Neurogen Corporation Substituted 4-oxo-napthyridine-3-carboxamides: GABA brain receptor ligands
JP2001514181A (ja) * 1997-08-25 2001-09-11 ニューロゲン コーポレイション Ｇａｂａ脳レセプタリガンドとしての置換４−オキソ−ナフチリジン−３−カルボキサミド
GB9805561D0 (en) * 1998-03-16 1998-05-13 Merck Sharp & Dohme A combination of therapeutic agents

Also Published As

Publication number Publication date
ZA200302918B (en) 2004-04-13
CA2426120A1 (en) 2002-04-25
US20050009861A1 (en) 2005-01-13
NZ525103A (en) 2004-12-24
EP1328294A2 (en) 2003-07-23
UY26970A1 (es) 2002-06-20
AU2001294117B2 (en) 2006-07-27
KR20030046509A (ko) 2003-06-12
AU9411701A (en) 2002-04-29
PE20020473A1 (es) 2002-06-14
US20020151591A1 (en) 2002-10-17
WO2002032412A2 (en) 2002-04-25
HUP0302476A3 (en) 2005-05-30
WO2002032412A3 (en) 2003-03-20
HUP0302476A2 (hu) 2003-11-28
JP2004511512A (ja) 2004-04-15
AR030893A1 (es) 2003-09-03

Similar Documents

Publication Publication Date Title
IL155225A0 (en) Combination use of acetylcholinesterase inhibitors and gabaa inverse agonists for the treatment of cognitive disorders
GB0007193D0 (en) Treatment of movrmrnt disorders
AU2002351397A8 (en) Systems and methods using vasoconstriction for improved thermal treatment of tissues
HUP0600103A2 (en) Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
MXPA03007960A (es) Compuestos y metodos para el tratamiento de desordenes urogenitales.
HUP0104676A3 (en) Compositions for the treatment of anorectal disorders and their use
EP1392292A4 (en) PYRANOINDAZOLES AND THEIR USE IN GLAUCOMA TREATMENT
AU5714601A (en) Methods for prevention and treatment of gastrointestinal disorders
HK1094909A1 (en) Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis il-18
HK1142833A1 (en) Methods for the treatment of cellular proliferative disorders
IL155589A0 (en) Novel amidoalkyl-piperidine and amidoalkyl-piperazine derivatives useful for the treatment of nervous system disorders
SI1627639T1 (sl) Uporaba inhibitorjev COX-2 za zdravljenje afektivnih motenj
IL162153A0 (en) Methods and compositions for treatment of central nervous systemdisorders
IL145481A0 (en) Compounds and methods for treatment of asthma, allergy and inflammatory disorders
IL155874A0 (en) Treatment of anxiety disorders
HUP0102886A3 (en) Treatment of anxiety disorders
EP1539100A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISORDERS
EP1315499A4 (en) COMPOSITIONS AND METHODS OF TREATING ANORCAL DISEASES
IL151493A0 (en) Use of dermaciclane for the treatment of anxiety and depression
EP1440080A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF CELLULAR PROLIFERATION DISORDERS INVOLVING THE 20750
AU2000270300A1 (en) Use of phosphodiesterase inhibitors for the treatment of anorectal disorders
IL142102A0 (en) Zinc-sensing receptor and methods of treatment of disorders associated herewith
EP1440165A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CELL PROLIFERATION DISORDERS USING 25943
SI1133290T1 (en) Use of inhibitors of acetylcholinesterase for the treatment of deliriums
SI1392292T1 (sl) Piranoindazoli in njihova uporaba pri zdravljenjuglavkoma